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OBJECTIVES: The objective of this study was to analyze medications that act on the cytochrome P450 (CYP450) enzymatic 
system and are used daily by non-institutionalized elderly individuals.
METHODS: A cross-sectional population-based study of elderly individuals (≥ 60 years old) was conducted. All continuously 
used medications with hepatic metabolism via CYP450 that are classified as substrates, inducers or inhibitors were considered. 
For the analysis, elderly individuals were stratified according to age groups, and hepatic metabolism activity due to daily alcohol 
consumption and smoking were considered.
RESULTS: Elderly individuals (396 in total: 222 women and 174 men) between 60 and 95 years of age (mean: 72.1) were assessed. 
Use of drugs that act on CYP450 was identified in 61.6% of the subjects. Drug use was observed among 16.2% of the subjects: 
three drugs among 9.8% and four or more among 6.3% of the subjects. The metabolic activities of the drugs used were classified 
as substrates (58.8%), inhibitors (14.9%), and inducers (4.3%). The main drugs used were beta-blockers and statins (as substrates), 
proton pump inhibitors and fluoxetine (as inhibitors), and prednisone and carbamazepine (as inducers). 
CONCLUSIONS: The results demonstrate that the elderly use high levels of medications that act on CYP450, thereby increasing 
the risk of drug interactions in a group that is already vulnerable to adverse drug effects. 
KEYWORDS: Aged; Pharmacoepidemiology; Cytochrome P450; Drug utilization; Drug-drug interaction. 
INTRODUCTION
The elderly population presents high rates of morbidity, 
functional incapacity, and the use of multiple medications. 
These factors establish a higher prevalence of adverse drug 
reactions, most of which are due to polypharmacy and drug 
interactions.1 
Drug interactions occur through concomitant use 
of drugs that can cause undesirable effects in the users. 
Pharmacokinetic and pharmacodynamic changes in the 
aging population establishes a higher vulnerability to 
drug interactions among the elderly.2,3 This interaction 
was identified in 44.5% of individuals in the geriatric 
population.4
Most pharmacokinetic interactions occur because of a 
drug’s effect on the cytochrome P450 (CYP450) enzymatic 
system, in which drugs take on the roles of inhibitors, 
inducers, or substrates of metabolic activity.5 There is 
genetic variability in the action of these enzymes, and this 
phenomenon may interfere with the patient’s response to the 
use of certain medications.6 
Some studies have observed frequent prescription of 
inappropriate medications among the geriatric populations.1,7,8 
However, despite the fact that elderly individuals represent 
a group with higher vulnerability to drug interactions, few 
authors have specifically analyzed the occurrence of this 
phenomenon among the elderly.
The present study was designed to identify the use of 
medications that may affect the CYP450 metabolism system 
among non-institutionalized elderly individuals by means of 
a home survey. 274
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MATERIALS AND METHODS
Study design: A population-based cross-sectional 
analytical study
Population and sampling:  Study  subjects  were 
individuals aged 60 years or more who were living in a 
district of the central region of the municipality of Londrina, 
Paraná, Brazil. The sample size was calculated using Epi-
Info (StatCalc) software, considering a margin of error of 
3%, a confidence interval of 95% and a possibility of losses 
of 20%. Selection of the elderly individuals was random with 
regard to the location of their homes, and the sample quotas 
were fulfilled in proportion to sex. 
Data collection: The data were obtained by means of 
a home survey carried out by teams of trained researchers 
between June and August 2007.
Variables analyzed:
o  Age – subjects were stratified into two groups for analy-
sis: from 60 to 74 years of age and 75 years or over. 
o  Sex.
o  Education level (years of study) – fewer than 4 years of 
study was used as the reference for a low education level.
o  Use of tobacco – only individuals who stated regular use 
of cigarettes at the time of the survey were considered as 
smokers. 
o  Daily alcohol consumption – individuals were classified 
as presenting daily alcohol consumption if they reported 
any daily intake of alcoholic drinks, regardless of the 
volume consumed.
o  Use of medications that act on CYP450 – medications 
used regularly and continuously that act on any enzyme 
in the CYP450 system were recorded and classified ac-
cording to whether they functioned as a substrate, inhibi-
tor, or inducer of metabolism9. 
o  Topical dermatological medications and medications not 
regularly used were excluded.
o  Botanical supplements that act on CYP450 such as St. 
John’s wort were considered. However, none of the par-
ticipants used such supplements. 
o  Because of the activity of nicotine and alcohol on 
CYP450 (substrate and/or inducer), users of drugs with 
substrate or inducer activities were grouped together with 
smokers or individuals who reported a daily intake of 
alcoholic drinks9. 
Statistical analyses
The data were analyzed using Epi-Info software, 
version 3.4.1. The chi-squared test was used for frequency 
comparisons between the sexes and age groups. ANOVA was 
used to compare age means. The number of medications with 
activity on CYP450 and the type of activity on the system 
are presented according to age group. The significance level 
was set at 95%.
Ethical issues
This project was approved by the research ethics 
committee of the State University of Londrina – Paraná – 
Brazil (number 261/06) in October 2006. Subjects signed 
a free and informed consent statement at the beginning of 
the interview.
RESULTS
Three hundred and ninety-six elderly individuals ranging 
from 60 to 95 years of age (mean: 72.1 years) were assessed. 
Of these subjects, 222 were women (56.1%) and 174 were 
men (43.9%). Men presented higher frequencies of daily 
consumption of alcoholic drinks and the use of tobacco. 
There was no difference in the level of education frequencies 
between the sexes (Table 1).
The use of drugs that act on the CYP450 system was 
observed among 61.6% of the elderly individuals, and the 
proportion among women was higher (67.6%) (Table 1). The 
Table 1 - Characteristics of the population analyzed according to sex
Variables
Total (396) 
N ( % )
Sex
p-value Male (174) 
N ( % )
Female (222) 
N ( % )
Age in years (mean) 72.1 72.2 72.0 0.74*
Low education level (< 4 years) 149 (37.6) 64 (36.8) 85 (38.3) 0.76
Use of tobacco 30 (7.6) 17 (9.8) 13 (5.9) 0.14
Daily consumption of alcoholic drinks 33 (8.3) 31 (17.8) 2 (0.9) < 0.000
Use of drugs that act on Cytochrome P450 244 (61.6) 94 (54.0) 150 (67.6) 0.006
* ANOVA275
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use of more than two drugs that act on CYP450 was recorded 
among 64 individuals (16.2%) (Table 2).
Drugs with substrate activity formed the most frequently 
used group (58.8%). This proportion became 66.9% when 
the elderly individuals who smoked and/or consumed daily 
alcoholic drinks were grouped into this category. The use 
of drugs with inhibitor activity on CYP450 was observed 
among 14.9% of the subjects. Only 4.3% of the subjects used 
drugs with inducer activity. The frequency of participants 
that used drugs with inducer activity and/or consumed 
alcoholic drinks on a daily basis was 18.2%. There was no 
difference in the profile of drugs used between the two age 
groups (Table 3).
Among the drugs classified as substrates, the most 
frequently used were beta-blockers and statins. Proton pump 
inhibitors were considered as both substrates and inhibitors. 
In addition to these, the other inhibitors identified were 
the antidepressants fluoxetine and paroxetine. The most 
frequently used inducers were prednisone and carbamazepine 
(Table 4). 
DISCUSSION
The results demonstrate that the elderly individuals 
assessed in the present study used a high number of 
medications that act on the CYP450 system. Most of the 
active drugs were classified as substrates, but some subjects 
also used drugs that were potential inhibitors and inducers.
In formulating geriatric prescriptions, it is very important 
to understand the effect of each drug on the CYP450 system, 
as drug interactions may enhance or reduce the drug’s 
activity while increasing adverse effects. 
This population-based study made it possible to analyze 
a representative group of non-institutionalized elderly 
individuals who frequently receive medical prescriptions for 
a wide variety of reasons.
Most (61.4%) of the elderly individuals analyzed used at 
least one drug that acted on CYP450, representing a higher 
potential for drug interactions. 
Some authors have already demonstrated the importance 
of these medications for the elderly population, and have 
observed an increase in the use of medications that carry a 
potential risk of drug interactions.10 In a previous study, 46% 
of geriatric patients were treated with at least one drug that 
is metabolized by CYP450.11 In another study of individuals 
with a history of stroke, Classen et al. observed that 60% to 
80% of these patients were using drugs that carry a risk of 
adverse interactions.12 
It is important to emphasize that in the present analysis, 
medications were only considered if they had been used 
continuously, although sporadic use may also play an 
important role in drug interactions. Furthermore, this study 
did not analyze the specific enzymatic activity of the drugs, 
and thus it was possible that an individual may use two 
or more drugs that act on the CYP450, but via different 
enzymes. Such a situation would not represent a risk for 
drug interaction.
Another important factor for the risk of drug interactions 
(that was not analyzed in the present study) is the possibility 
of polymorphisms that give rise to a pharmacogenetic 
characteristic for users of the medication.13 Despite the 
fact that genetic variability is an important determinant of 
enzymatic activity, racial factors could not be assessed due 
to the multiracial Brazilian population. 
Table 2 - Distribution of the number of drugs used that act 
on CYP450 according to age group
Number of 
drugs that act on 
CYP450
Total 
(396) 
N (%)
Age group*
60 – 74 years 
(240) 
N (%)
75 years or over 
(156) 
N (%)
0 152 (38.4) 96 (40.0) 56 (35.9)
1 108 (27.3) 65 (27.1) 43 (27.3)
2 72 (18.2) 46 (19.2) 26 (16.7)
3 39 (9.8) 23 (9.6) 16 (10.3)
4 15 (3.8) 7 (2.9) 8 (5.1)
5 9 (2.3) 3 (1.3) 6 (3.8)
6 1 (0.3) 0 (0.0) 1 (0.6)
*p = 0.3
Table 3 - Distribution of the drugs used according to the type of activity exerted on the CYP450 system and the age group
Type of activity on CYP450
Total (396) 
N (%)
Age group
p-value 60 – 74 years 
(240) N (%)
75 years or over 
(156) N (%)
Substrate 233 (58.8) 138 (57.5) 95 (60.9) 0.50
Substrate and/or smoker and/or daily consumption of alcohol 265 (66.9) 163 (67.9) 102 (65.4) 0.67
Metabolism inhibitor 59 (14.9) 32 (13.3) 27 (17.3) 0.27
Metabolism inducer 17 (4.3) 10 (4.2) 7 (4.5) 0.88
Inducer and/or smoker and/or daily consumption of alcohol 72 (18.2) 48 (20.0) 24 (15.4) 0.24276
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In addition to inter-individual variability, frailty and age-
related changes in pharmacology must be considered when 
adverse drug events are assessed in the elderly.14 
Our data revealed that elderly women used more 
CYP450-active drugs than men, and represented a higher 
risk for adverse drug events. Moreover, some sex differences 
in pharmacology (renal clearance, volume distribution, and 
CYP450 activity) were found to increase the female risk.15
There were no differences in the number of drugs 
used between the two age groups, but the group of elderly 
individuals aged 75 years or more may present a higher risk 
of drug interaction than that shown by the individuals aged 
60 to 75 years. As people age, their hepatic metabolism rate 
changes, which increases elderly individuals’ vulnerability 
to drugs that act on CYP450. Moreover, greater use of such 
medications and a higher prevalence of comorbidities, which 
contribute to the increased risk of adverse drug effects, were 
observed.16
Comorbidity represents a point of vulnerability among 
geriatric patients. Hepatic metabolism changes in disease 
states that are frequently observed in elderly patients, such as 
hypertension, diabetes, and obesity. In general, these patients 
possess low enzymatic activity due to their diseases, thereby 
increasing the risk of adverse effects.17 
Approximately one third of the elderly individuals 
examined used two or more drugs that acted on CYP450, thus 
representing a potential drug complication. Johnell and Klarin 
studied elderly individuals (aged 75 years or over), and found 
a notable association between the number of drugs used and 
the risk of serious drug interactions in this population.18 
Many drugs that are frequently used during day-to-
day clinical practice are metabolized by the CYP450 
system, and are classified as substrates. These drugs 
include antihypertensive drugs (beta-adrenergic blockers, 
Angiotensin II receptor blockers, and calcium channel 
blockers) and statins, which present evidence of benefits in 
clinical practice. Therefore, their use should be encouraged, 
despite the higher risk of drug interactions. However, we 
identified the use of drugs such as benzodiazepines, anti-
histamines, non-hormonal anti-inflammatory drugs, and 
tricyclic antidepressants, which not only represent a risk 
of drug interaction, but also are considered inappropriate 
for elderly due to their toxicity or low efficiency.19,20 The 
frequency of benzodiazepine use was higher than that 
observed by other authors in both Brazil 21,22 and European 
countries.23 
Among the group of subjects who used drugs with 
inhibitor activity on CYP450, use of the antidepressants 
fluoxetine and paroxetine must be highlighted. These 
medications present an unfavorable metabolic profile for 
the elderly population and a greater risk of serotoninergic 
syndrome.24 Nevertheless, they are commonly used among 
this population because of their lower costs. 
Proton pump inhibitors present a wide range of activities 
on CYP450 and are currently widely used in clinical 
practice. Those who prescribe these drugs must consider the 
metabolic characteristics of the other medications in use, 
thereby minimizing the risk of a drug interaction.
Anti-convulsants (carbamazepine, phenobarbital, and 
phenytoin) and prednisone were the drugs that act on 
Table 4 - Drugs used according to their action on the CYP450 
system
Drug N (%)
Substrates
Beta-adrenergic blockers 85 (21.5)
Statins 77 (19.4)
Angiotensin II receptor blockers 48 (12.1)
Calcium channel blockers 28 (7.1)
Benzodiazepines 27 (6.8) 
Proton pump inhibitors 25 (6.3)
Nonsteroidal anti-inflammatory drugs 24 (6.1)
Paracetamol 18 (4.6)
Tricyclic antidepressants  11 (2.8)
Antihistamines 5 (1.3)
Warfarin 4 (1.0)
Glitazones 3 (0.8)
Cyclobenzaprine 2 (0.5)
Antipsychotics 2 (0.5)
Phenytoin 2 (0.5)
Lamotrigine 1 (0.3)
Zolpidem 1 (0.3)
Inhibitors 
Proton pump inhibitors 25 (6.3)
Fluoxetine 16 (4.0)
Paroxetine 7 (1.8)
Ticlopidine 6 (1.5)
Amiodarone 5 (1.3)
Fluvoxamine 1 (0.3)
Venlafaxine 1 (0.3)
Griseofulvin 1 (0.3)
Fluconazole 1 (0.3)
Inducers
Prednisone 7 (1.8)
Carbamazepine 5 (1.3)
Phenobarbital 3 (0.8)
Phenytoin 2 (0.5)
Rifampin 1 (0.3)277
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CYP450 as inducers used by the elderly individuals studied. 
The inducing action may result in a lower efficiency of other 
concomitantly used medications, or of the production of 
toxic metabolites.9,25
Although a potential drug-herb interaction may occur due 
to the inducer action of St. John’s wort,26 the use of herbal 
preparations was not observed in this population. Social and 
cultural characteristics of the population and conditions of 
the local health service could account for this. 
In addition to the metabolic activity of the drugs used, 
the effect of nicotine and alcohol on CYP450 was also 
considered in this analysis. The possibility of substrate 
activity increased from 58.8% to 66.9% when individuals 
who smoked and consumed daily quantities of alcohol 
were also included. The use of inducers increased from 
4.3% to 18.2% when the consumption of alcohol or use of 
tobacco was taken into account. In medical practice, the 
possibilities for pharmacological interference due to the use 
of tobacco and alcohol must be kept in mind, in addition 
to the well-known and disseminated problems related to 
health maintenance that are caused by these two behavioral 
patterns. 
The data presented herein draw attention to the 
possibility of drug interactions in elderly patients that may 
be caused by the use of drugs that act on the CYP 450 
system. The need for a better understanding of the activity 
pattern of drugs that are important in clinical practice and 
for knowledge of the determinants of adverse effects from 
these drugs is necessary when prescribing medication for the 
elderly.27 Some authors have shown that careful evaluation 
of drug regimes resulted in a reduction of the adverse effects 
observed in geriatric outpatients taking more than one drug4, 
and reduced preventable prescribing errors by 13% in older 
patients28 
Therefore, with respect to medical care of the elderly, 
the use of medications metabolized by the CYP450 system 
must follow the risk and benefit criteria that are pertinent to 
this age group. 
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